Sector Gamma AS lifted its stake in shares of Portola Pharmaceuticals (NASDAQ:PTLA) by 169.6% during the 1st quarter, Holdings Channel reports. The institutional investor owned 134,800 shares of the biopharmaceutical company’s stock after buying an additional 84,800 shares during the period. Portola Pharmaceuticals makes up about 0.8% of Sector Gamma AS’s portfolio, making the stock its 26th largest position. Sector Gamma AS’s holdings in Portola Pharmaceuticals were worth $4,403,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Portola Pharmaceuticals by 6.7% during the fourth quarter. BlackRock Inc. now owns 4,696,591 shares of the biopharmaceutical company’s stock worth $228,629,000 after acquiring an additional 293,802 shares during the period. Kornitzer Capital Management Inc. KS lifted its holdings in Portola Pharmaceuticals by 29.5% during the first quarter. Kornitzer Capital Management Inc. KS now owns 1,069,944 shares of the biopharmaceutical company’s stock worth $34,944,000 after acquiring an additional 243,917 shares during the period. Fred Alger Management Inc. lifted its holdings in Portola Pharmaceuticals by 4.5% during the fourth quarter. Fred Alger Management Inc. now owns 756,425 shares of the biopharmaceutical company’s stock worth $36,823,000 after acquiring an additional 32,694 shares during the period. Wells Fargo & Company MN lifted its holdings in Portola Pharmaceuticals by 1,367.8% during the fourth quarter. Wells Fargo & Company MN now owns 686,816 shares of the biopharmaceutical company’s stock worth $33,434,000 after acquiring an additional 640,023 shares during the period. Finally, Deutsche Bank AG lifted its holdings in Portola Pharmaceuticals by 2.9% during the fourth quarter. Deutsche Bank AG now owns 631,007 shares of the biopharmaceutical company’s stock worth $30,715,000 after acquiring an additional 18,012 shares during the period. 85.56% of the stock is currently owned by institutional investors.
Get Portola Pharmaceuticals alerts:
A number of analysts recently commented on PTLA shares. BidaskClub lowered Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 21st. Oppenheimer set a $80.00 price target on Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Sunday, May 6th. ValuEngine lowered Portola Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, March 1st. Zacks Investment Research upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 7th. Finally, Morgan Stanley lowered their target price on Portola Pharmaceuticals from $74.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, February 22nd. Four investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Portola Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $64.86.
Shares of PTLA opened at $40.64 on Thursday. The firm has a market capitalization of $2.67 billion, a price-to-earnings ratio of -8.45 and a beta of 1.48. The company has a debt-to-equity ratio of 0.35, a quick ratio of 7.53 and a current ratio of 7.59. Portola Pharmaceuticals has a 1 year low of $39.92 and a 1 year high of $40.79.
Portola Pharmaceuticals (NASDAQ:PTLA) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by ($0.06). The firm had revenue of $6.64 million during the quarter, compared to the consensus estimate of $3.20 million. Portola Pharmaceuticals had a negative net margin of 1,364.89% and a negative return on equity of 109.35%. The business’s quarterly revenue was up 29.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.74) earnings per share. research analysts anticipate that Portola Pharmaceuticals will post -4.98 earnings per share for the current fiscal year.
In other Portola Pharmaceuticals news, EVP Tao Fu sold 1,135 shares of the business’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $38.47, for a total value of $43,663.45. Following the sale, the executive vice president now directly owns 18,346 shares in the company, valued at $705,770.62. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 4.60% of the company’s stock.
Portola Pharmaceuticals Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. The company is developing Betrixaban, an oral once-daily Factor Xa inhibitor for hospital and extended duration prophylaxis of venous thromboembolism in adults hospitalized for an acute medical illness; Andexanet alfa, a recombinant protein that is in Phase III study for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, a spleen tyrosine kinase inhibitor, which is in Phase IIa clinical stage to treat hematologic cancers.
Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals (NASDAQ:PTLA).